top of page


Biocon expands Yesintek biosimilar licensing rights to nine additional international markets
Biocon has secured additional licensing rights for its Yesintek ustekinumab biosimilar across nine international markets, broadening its planned commercial footprint.

nuaxia
Oct 272 min read


Samsung Bioepis gains Japanese approval for intravenous Stelara biosimilar
Samsung Bioepis has received Japanese marketing approval for a 130mg intravenous formulation of its ustekinumab biosimilar referencing Stelara.

nuaxia
Sep 41 min read
bottom of page